Clinical Trial

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC. Approximately 138 participants who meet all eligibility criteria will be enrolled in the study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-03.
Trial Details
NCT Number NCT07395232
Lead Sponsor Dompé Farmaceutici S.p.A
Conditions Atopic Keratoconjunctivitis
Enrollment 138 participants
Start Date 2025-12-01
Primary Completion 2027-03 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-04-20